Kelsey Achenbach’s Post

View profile for Kelsey Achenbach, graphic

Vice President, Pharmaceutical Business

Taste is a major consideration when creating patient-friendly, palatable drug products that support compliance. This means overcoming the bitter profile present in more than 60% of APIs. To address this, and support patient-first innovation, our brilliant flavor specialists here at dsm-firmenich have harnessed decades of expertise and scientific understanding to develop advanced bitter blockers.     My teammates, Guy Servant, Ph.D, Head of Taste Receptor-Based Discovery, and Lyzandra Passarella-Dutour, M.Sc., Global Taste Technical Director, recently shared their insights and strategies for addressing API bitterness in a AAPS eCHALK TALK session, now available on demand.    👉 Watch it here to uncover valuable learnings: https://lnkd.in/dFcEDqwC    #excipients #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth 

Specialty Excipients | dsm-firmenich Pharma Solutions

Specialty Excipients | dsm-firmenich Pharma Solutions

dsm.com

Shawn Branning

Business Line Owner, Commercial Accelerator, and Global Strategist for Public and Private Equity Businesses | MBA

4mo

This is a tremendously critical aspect of drug formulation and ultimately, patient compliance. It's exciting to see the combined organization taking this on.

Like
Reply

To view or add a comment, sign in

Explore topics